TaiGen Biopharmaceuticals Holdings Limited (TPEX:4157)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
10.05
-0.05 (-0.50%)
Apr 28, 2026, 1:30 PM CST
5.57%
Market Cap 7.19B
Revenue (ttm) 259.47M
Net Income (ttm) 45.18M
Shares Out 711.83M
EPS (ttm) 0.06
PE Ratio 168.33
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 430,672
Average Volume 1,292,046
Open 10.10
Previous Close 10.10
Day's Range 10.00 - 10.20
52-Week Range 7.44 - 16.40
Beta 0.35
RSI 34.00
Earnings Date May 13, 2026

About TPEX:4157

TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. Its product pipeline comprises Taigexyn, which is in phase II clinical trial for the treatment of community-acquired pneumonia/diabetic foot infection; TG-1000, which is in phase III clinical trial to treat influenza A and B, and avian influenza H7N9; Furaprevir, a HCV protease inhibit... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Country Cayman Islands
Stock Exchange Taipei Exchange
Ticker Symbol 4157
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.